Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
|Videos|July 22, 2017
Good Neighbor Pharmacy of the Year Winner Named
Each finalist was chosen out of 50 nominees.
Advertisement
St. George Pharmacy in Staten Island, NY was announced at
The video below details how this pharmacy owner, Al Gentile, and others in the pharmacy made a difference in their community during both the September 11 attacks on New York, and several years later, following Hurricane Sandy.
Each finalist was chosen out of 50 nominees. See more about the pharmacies at
Advertisement
Related to this article
At NEIAP 2026, Kelsey Norman, PharmD, walked through how VESALIUS-CV, Lp(a)HORIZON, and CKM guidelines change pharmacist-led lipid care.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Psilocybin-Assisted Therapy for AUD: Emerging Evidence, Clinical and Cost Implications, and Treatment Gaps
5